臭氧自血回输疗法用于新型冠状病毒肺炎治疗之建议  

Proposal on utilizing ozonated autohemotherapy in the treatment of COVID-19 viral infection

作　　者：莫世湟 李贺[1] Martin Mok;Li He(Department of Pain Medicine,the Eighth Affiliated Hospital of Sun Yat-Sen University,Shenzhen 518033,China)

机构地区：[1]中山大学附属第八医院疼痛科,深圳市518033

出　　处：《中华疼痛学杂志》2020年第3期194-196,共3页Chinese Journal Of Painology

摘　　要：臭氧自血回输疗法自2000年被引入中囯,现已广为疼痛科医师使用,并且已证明其有抗病毒、抗炎、镇痛、免疫调节功能,对纠正组织乏氧、清除自由基方面有良好的作用。2019年12月开始,新型冠状病毒肺炎(COVID-19)席卷全球,现有超过一百万确诊病例(WHO世界卫生组织,2020年4月3日公布之数据)及较高的死亡率。目前应对新型冠状病毒肺炎尚无特效药物,也没有疫苗,考虑到臭氧自血回输疗法有上述抗病毒与抗炎之功能,笔者建议考虑将其加入新型冠状病毒肺炎治疗方案做相关临床研究。Ozonated autohemotherapy has been widely used by the pain specialist in China since 2000 and it had been proven to be valuable in the treatment of antiviral,anti-infection,analgesia,immunomodulation,oxygen deficit,removing free radicals and metabolic disorders.Since December 2019 a newly discovered coronar virus infection(COVID-19)has swept the world causing a global pandemic with over 1 million diagnosed cases and significant mortalities(WHO released figure on 2020 April 3).At present there is no specific treatment or vaccine for this disease.Drawing from its clinical effects we postulate that ozone autohemotherapy would be of value in treating COVID-19 worthy well designed clinical studies.

关 键 词：臭氧自血回输治疗 新型冠状病毒肺炎 病毒 

分 类 号：R563.1[医药卫生—呼吸系统]